Targeted protein degradation (TPD) is a cutting edge therapeutic modality with the potential to destroy disease-causing proteins that have historically been undruggable with conventional small molecules.

Unlike conventional drugs that only inhibit the activity of disease-causing proteins, targeted protein degraders completely destroy the protein.

At Ternarx, a WEHI spinout company, researchers are using TPD technology to develop new treatments for cancer and other diseases.

Read more: https://www.wehi.edu.au/ternarx/